, (GLOBE NEWSWIRE) -- (NASDAQ:TGTX) today announced the pricing of an underwritten public offering of 5,128,206 shares of its common stock at a price of per share, with expected gross proceeds to of . In addition, has granted the underwriters a 30-day option to purchase up to an additional 769,230 shares of common stock at the public offering price, less underwriting discounts and commissions.
The offering is expected to close on or about subject to the satisfaction of customary closing conditions.
is acting as sole book-running manager for the offering. and are acting as lead managers. , , and are acting as co-managers for the offering.
TG Therapeutics intends to use the net proceeds of this offering to fund the ongoing development of TG-1101 and TGR-1202, to potentially in-license, acquire, develop and commercialize additional drug candidates, for research and development activities and for general corporate purposes.
The offering is being made pursuant to a shelf registration statement previously filed with the (the "SEC") on .
The offering is being made only by means of a written prospectus and prospectus supplement that form a part of the registration statement. A preliminary prospectus supplement and the accompanying prospectus related to the offering has been filed with the and is available on the website of the at www.sec.gov.
Copies of the preliminary prospectus supplement and accompanying prospectus, when available, may also be obtained from , Attention: , , 2nd Floor, , 10022, or by telephone at 877-821-7388, or by email at [email protected]
This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of, these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
ABOUT TG THERAPEUTICS, INC.
TG Therapeutics is a biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for B-cell malignancies and autoimmune diseases.
Currently, the company is developing two therapies targeting hematological malignancies and autoimmune diseases. TG-1101 (ublituximab) is a novel, glycoengineered monoclonal antibody that targets a specific and unique epitope on the CD20 antigen found on mature B-lymphocytes.
TG Therapeutics is also developing TGR-1202, an orally available PI3K delta inhibitor. The delta isoform of PI3K is strongly expressed in cells of hematopoietic origin and is believed to be important in the proliferation and survival of B‐lymphocytes.
Both TG-1101 and TGR-1202 are in clinical development for patients with hematologic malignancies, with TG-1101 also in clinical development for autoimmune disorders. The Company also has pre-clinical programs to develop IRAK4 inhibitors, BET inhibitors, and anti-PD-L1 and anti-GITR antibodies.
Initial Public Offering (IPO) Process
TG Therapeutics is headquartered in New York City.
Some of the statements included in this press release may be forward-looking statements that involve a number of risks and uncertainties. For those statements, we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. The factors that could cause our actual results to differ materially include: statements regarding the proposed public offering and the intended use of proceeds from the proposed offering; the success and timing of our clinical trials and preclinical studies for our product candidates, including site initiation, internal review board approval, scientific review committee approval, patient accrual, safety, tolerability and efficacy data observed, and input from regulatory authorities; our plans to develop and commercialize our product candidates; market acceptance of our products; reimbursement available for our products; our available cash and investments; our ability to obtain and maintain intellectual property protection for our product candidates; our ability to manufacture; the performance of third-party manufacturers, clinical research organizations, clinical trial sponsors and clinical trial investigators; and other risk factors identified from time to time in our reports filed with the .
Any forward-looking statements set forth in this press release speak only as of the date of this press release. We do not undertake to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof.
This press release and prior releases are available at www.tgtherapeutics.com. The information found on our website is not incorporated by reference into this press release and is included for reference purposes only.
TGTX-GContact Vice President, Investor Relations Telephone: 212.554.4351 Email: [email protected]
News Provided by Acquire Media